Related Experiment Video

Updated: Aug 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

[Molecular target structures in oncology]

K Spiekermann1, W Hiddemann

  • 1Klinische Kooperationsgruppe Leukämie, Medizinische Klinik III, Klinikum Grosshadern der Ludwig-Maximilians-Universität München und GSF-Hämatologikum, Marchioninistrasse 15, 81377, München, Germany. karsten.spiekermann@med.uni-muenchen.de

Der Internist
|July 12, 2005
PubMed

Insights

Recent advances in oncology focus on molecular targets for "targeted therapies." Inhibitors of protein tyrosine kinases (PTKs) and monoclonal antibodies show promise in treating various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Understanding the molecular basis of cancer has led to the development of targeted therapies.
  • Signaling cascades, such as protein tyrosine kinases (PTKs), are frequently dysregulated in malignant disorders.
  • Tumor-specific cell surface proteins offer targets for antibody-based therapies.

Purpose:

  • To review the progress in identifying and targeting molecular pathways in cancer.
  • To highlight the therapeutic potential of small molecule inhibitors and monoclonal antibodies.
  • To emphasize the integration of diagnostics and therapeutics in oncology.

Summary:

  • Targeted therapies exploit molecular alterations driving cancer, including activated protein tyrosine kinases (PTKs) and tumor-specific cell surface proteins.
  • Small molecule inhibitors targeting PTKs have shown significant clinical responses in cancers like chronic myeloid leukemia and non-small cell lung cancer.
  • Monoclonal antibodies targeting cell surface proteins have improved outcomes in lymphomas and are being explored for other malignancies.

Impact:

  • Molecularly targeted therapies represent a paradigm shift in cancer treatment, moving towards personalized medicine.
  • The identification of critical molecular targets is crucial for developing effective integrated diagnostic and therapeutic strategies.
  • This approach holds the potential to significantly improve patient response rates and outcomes across various cancer types.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.